ESR1 and breast carcinoma: Also, previous research has shown that mTOR activities may be higher among patients with breast cancer with earlier (vs. more advanced) stage, lower (vs. higher) grade, smaller (vs. larger) tumors, and ER+ (vs. ER−) tumors (24).